Literature DB >> 21651699

The global health burden of hepatitis C virus infection.

Francesco Negro, Alfredo Alberti.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21651699     DOI： 10.1111/j.1478-3231.2011.02537.x

Source DB:  PubMed          Journal:  Liver Int        ISSN： 1478-3223            Impact factor:   5.828


× No keyword cloud information.
  40 in total

1.  Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.

Authors:  Young-Chan Kwon; Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

2.  A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs.

Authors:  T Spelman; M D Morris; G Zang; T Rice; K Page; L Maher; A Lloyd; J Grebely; G J Dore; A Y Kim; N H Shoukry; M Hellard; J Bruneau
Journal:  J Epidemiol Community Health       Date:  2015-03-26       Impact factor: 3.710

3.  Real-life cost of managing chronic HCV infection in Greece prior to Direct-Acting Antivirals (DAAs): an undeniable truth of spending more for less.

Authors:  K Souliotis; S Siakavellas; C Golna; E Manesis; G Papatheodoridis; A Hatzakis
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

4.  Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.

Authors:  Erik Mogalian; Polina German; Brian P Kearney; Cheng Yong Yang; Diana Brainard; John McNally; Lisa Moorehead; Anita Mathias
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.

Authors:  Gulam Hussain Syed; Huihui Tang; Mohsin Khan; Tarek Hassanein; Jingwen Liu; Aleem Siddiqui
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

6.  Discovery of Imidazo[1,2-α][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor.

Authors:  Huan Wang; Shuo Wang; Lili Cheng; Ligong Chen; Yongguang Wang; Jie Qing; Shengdian Huang; Yuanhao Wang; Xiaoqiang Lei; Yunfei Wu; Zhilong Ma; Linqi Zhang; Yefeng Tang
Journal:  ACS Med Chem Lett       Date:  2015-07-27       Impact factor: 4.345

7.  Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.

Authors:  Simon Giroux; Jinwang Xu; T Jagadeeswar Reddy; Mark Morris; Kevin M Cottrell; Caroline Cadilhac; James A Henderson; Oliver Nicolas; Darius Bilimoria; Francois Denis; Nagraj Mani; Nigel Ewing; Rebecca Shawgo; Lucille L'Heureux; Subajini Selliah; Laval Chan; Nathalie Chauret; Francoise Berlioz-Seux; Mark N Namchuk; Anne-Laure Grillot; Youssef L Bennani; Sanjoy K Das; John P Maxwell
Journal:  ACS Med Chem Lett       Date:  2013-01-27       Impact factor: 4.345

8.  Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.

Authors:  Il Hak Bae; Jin Kyu Choi; Chieyeon Chough; Sun Ju Keum; Heesun Kim; Sung Key Jang; B Moon Kim
Journal:  ACS Med Chem Lett       Date:  2013-12-04       Impact factor: 4.345

Review 9.  Transfusion transmission of HCV, a long but successful road map to safety.

Authors:  Suganya Selvarajah; Michael P Busch
Journal:  Antivir Ther       Date:  2012-12-07

10.  Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture.

Authors:  Mei Yu; Betty Peng; Katie Chan; Ruoyu Gong; Huiling Yang; William Delaney; Guofeng Cheng
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.